MedTrace Logo

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

NCT03419897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Tislelizumab

Administered intravenously

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-09
Primary Completion
2021-06-30
Completion
2022-07-06
FDA Drug
Yes

Countries

  • China
  • France
  • Germany
  • Italy
  • Poland
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03419897 on ClinicalTrials.gov